BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38113354)

  • 1. Electrophilic MiniFrags Revealed Unprecedented Binding Sites for Covalent HDAC8 Inhibitors.
    Keeley AB; Kopranovic A; Di Lorenzo V; Ábrányi-Balogh P; Jänsch N; Lai LN; Petri L; Orgován Z; Pölöske D; Orlova A; Németh AG; Desczyk C; Imre T; Bajusz D; Moriggl R; Meyer-Almes FJ; Keserü GM
    J Med Chem; 2024 Jan; 67(1):572-585. PubMed ID: 38113354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
    Muth M; Jänsch N; Kopranovic A; Krämer A; Wössner N; Jung M; Kirschhöfer F; Brenner-Weiß G; Meyer-Almes FJ
    Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):577-585. PubMed ID: 30611847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors.
    He B; Velaparthi S; Pieffet G; Pennington C; Mahesh A; Holzle DL; Brunsteiner M; van Breemen R; Blond SY; Petukhov PA
    J Med Chem; 2009 Nov; 52(22):7003-13. PubMed ID: 19886628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
    Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
    Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
    Thangapandian S; John S; Lee Y; Kim S; Lee KW
    Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
    Adhikari N; Amin SA; Jha T
    Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetically selective and potent inhibitors of HDAC8.
    Schweipert M; Jänsch N; Sugiarto WO; Meyer-Almes FJ
    Biol Chem; 2019 May; 400(6):733-743. PubMed ID: 30521473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
    Darwish S; Ghazy E; Heimburg T; Herp D; Zeyen P; Salem-Altintas R; Ridinger J; Robaa D; Schmidtkunz K; Erdmann F; Schmidt M; Romier C; Jung M; Oehme I; Sippl W
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
    Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
    Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8.
    Kopranovic A; Meyer-Almes FJ
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
    Thangapandian S; John S; Sakkiah S; Lee KW
    Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors.
    Huang WJ; Wang YC; Chao SW; Yang CY; Chen LC; Lin MH; Hou WC; Chen MY; Lee TL; Yang P; Chang CI
    ChemMedChem; 2012 Oct; 7(10):1815-24. PubMed ID: 22907916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.